SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease

por Savage, Martin, Shah, Nalini, Wojna, Judi, Han, Kevin, Roughton, Michael, Combes, François Pierre, Pultar, Philippe, Storr, Helen
Publicado 2019

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

por Fleseriu, Maria, Petersenn, Stephan, Biller, Beverly M. K., Kadioglu, Pinar, De Block, Christophe, T'Sjoen, Guy, Vantyghem, Marie‐Christine, Tauchmanova, Libuse, Wojna, Judi, Roughton, Michael, Lacroix, André, Newell‐Price, John
Publicado 2019

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled P...

por Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Hofstetter, Georg, Pedroncelli, Alberto M, Snyder, Peter J
Publicado 2021

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

por Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Yu, Yerong, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Pedroncelli, Alberto M, Snyder, Peter J
Publicado 2022